Evidence map›Paper›PMID 35813628›Full record

Trial reportFrontiers in endocrinology2022

The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial.

Rongzhen Tao, Jianhuai Chen, Dujian Wang, Yunpeng Li, Jun Xiang, Lei Xiong, Junbiao Ji, Jie Wu, Shuang Zhou, Chunping Jia and 3 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Penile prosthesis implantation: a bibliometric-based visualization study.International journal of impotence research · 2025
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Rongzhen TaoDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Jianhuai ChenDepartment of Andrology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Dujian WangDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Yunpeng LiDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Jun XiangDepartment of Ultrasound, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Lei XiongDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Junbiao JiDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Jie WuDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Shuang ZhouDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Chunping JiaDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Jianlin LvDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Jie YangDepartment of Urology, Jiangsu Provincial People's Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qinglai TangDepartment of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Jiangning Hospital · CNNanjing Medical University · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Phosphodiesterase type 5-inhibitors (PDE5is) are the first-line treatment for patients with diabetes mellitus-induced erectile dysfunction (DMED), however, some patients are non-responser to PDE5is. We performed a perspective, randomized, comparative study to explore the efficacy of low intensity extracorporeal shock wave treatment (Li-ESWT) combined with vacuum erectile device (VED) in the treatment of DMED patients who were unresponsive to PDE5is. Methods: One hundred and five eligible patients were randomly divided into three groups: group A (VED), group B (Li-ESWT) and group C (VED plus Li-ESWT). Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the end of treatment. The erectile function was estimated by the international index of erectile function-erectile function domain (IIEF-EF), erection hardness score (EHS), sexual encounter profile questions 2 and 3 (SEP2 and SEP3) and global assessment question 1 and 2 (GAQ1 and GAQ2) before and after treatment. The changes of five points in IIEF-EF were calculated as the minimal clinical important difference (MCID), which was considered as the main index of efficacy. Results: The MCID was achieved in 14.7%, 14.7% and 17.6% patients in group A at the follow up on 4 weeks, 8 weeks and 12 weeks, respectively (36.4%, 39.4% and 36.4% in group B; 36.4%, 51.5%, and 66.7% in group C). There were significant differences in the percentage of MCID cases between group A and group C at the follow up on 12 weeks ( Conclusion: Our findings indicated the combined therapy Li-ESWT and VED was more beneficial to shift turn PDE5is non-responders to responders for moderate patients with DMED than VED or Li-ESWT monotherapy. Moreover, this study provided evidence that patients with DMED who failed after taking oral PDE5is could attempt to opt for an alternative physicotherapy (Li-ESWT or VED) prior to more invasive alternatives.

Indexed as

Diabetes MellitusErectile DysfunctionHumansMalePenile ErectionPhosphodiesterase 5 InhibitorsTreatment OutcomePhosphodiesterase 5 Inhibitorsdiabetes mellituserectile dysfunctionlow intensity extracorporeal shock wave treatmentphosphodiesterase type 5-inhibitorsvacuum erectile device

Identifiers

PMID35813628
PMCPMC9259797
OpenAlexW4283322152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.